Federal Circuit Affirms Ruling in Truveris v. Skysail Rx Prescription Drug Plan Patent Case
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Truveris, Inc. v. Skysail Concepts, LLC dba Skysail Rx, LLC |
| Case Number | 23-1024 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from District of Columbia Circuit |
| Duration | Oct 12, 2022 – Apr 3, 2024 1 year 5 months |
| Outcome | Plaintiff Win — Appeal Affirmed (Rule 36) |
| Patents at Issue | |
| Accused Products | Skysail Rx Prescription Drug Plan Management System/Service |
Case Overview
The Parties
⚖️ Plaintiff
Truveris, Inc. is a healthcare data analytics company focused on pharmacy benefit intelligence and drug plan optimization. Its platforms serve payers, employers, and health plans seeking transparency and cost efficiency in prescription drug selection — a high-value commercial segment that has attracted significant IP development and competition.
🛡️ Defendant
Skysail Concepts, LLC, doing business as Skysail Rx, LLC, operates in the prescription drug plan services space. The company’s accused product or service allegedly replicated methods claimed in Truveris’s patent portfolio, making this a direct competitive dispute between market participants in an increasingly crowded sector.
The Patent at Issue
This landmark case involved U.S. Patent No. US10817920B2, which covers a “system and method for managing selection of prescription drug plans” — a commercially significant technology area as digital health platforms and pharmacy benefit management systems continue to reshape how patients and payers navigate prescription coverage.
- • US10817920B2 — System and method for managing selection of prescription drug plans
Designing a similar drug plan management system?
Check if your prescription drug plan design might infringe this or related health technology patents before launch.
The Verdict & Legal Analysis
Outcome
The Federal Circuit affirmed the lower tribunal’s ruling, entering its judgment with the standard Rule 36 notation: “THIS CAUSE having been heard and considered, it is ORDERED and ADJUDGED: AFFIRMED.” The basis of termination was recorded as **Appeal Dismissed**, consistent with a Rule 36 affirmance that effectively closes appellate review without issuing a written precedential opinion. No specific damages amounts were publicly disclosed in the available case record.
Key Legal Issues
Federal Circuit Rule 36 allows the court to affirm a lower court’s judgment without a written opinion when the court determines that one of the following applies: the judgment is based on findings not clearly erroneous; no error of law was committed; or the issues were presented in a prior opinion. For practitioners, a Rule 36 judgment carries a specific strategic message — the lower court got it right, and the appealing party failed to demonstrate reversible error on claim construction, infringement analysis, or any procedural grounds that would warrant written elaboration.
The technology at issue — software-implemented systems for prescription drug plan selection — sits at the intersection of patent-eligible subject matter doctrine and practical claim drafting. Health technology patents covering algorithmic or data-driven methods have faced persistent § 101 eligibility challenges since Alice Corp. v. CLS Bank International (2014). The fact that this patent survived to produce an affirmed infringement ruling suggests that claim drafting and eligibility arguments were either not central to the appeal or were resolved in Truveris’s favor at the district court level.
Freedom to Operate (FTO) Analysis in Health Tech
This case highlights critical IP risks in prescription drug plan management. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation in health technology.
- View related patents in the health tech space
- See which companies are most active in PBM patents
- Understand claim construction patterns for software-implemented healthcare patents
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product in the PBM space.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Software-implemented drug plan selection systems
1 Patent at Issue
Covering PBM core functionality
Design-Around Options
Available for most claims in software-implemented systems
✅ Key Takeaways for Health Technology IP
Federal Circuit Rule 36 affirmances signal that the lower court’s record was legally sound; build an airtight trial record to foreclose appellate reversal opportunities.
Search related case law →Software-implemented healthcare patents remain enforceable at the Federal Circuit if properly drafted and prosecuted.
Explore precedents →Health IT patent litigation from filing to Federal Circuit resolution can exceed 18 months — plan litigation budgets accordingly.
Track litigation timelines →Monitor US10817920B2 and related Truveris portfolio filings for continuation or divisional patents that could expand claim coverage.
Analyze patent families →Frequently Asked Questions about Health Tech Patents
The case involved U.S. Patent No. US10817920B2 (Application No. US13/999121), covering a system and method for managing selection of prescription drug plans.
The Federal Circuit affirmed the lower court’s ruling via a Rule 36 judgment on April 3, 2024, effectively upholding the infringement action outcome in favor of Truveris, Inc.
The affirmance confirms that software-implemented drug plan management patents can be enforced through Federal Circuit review, signaling meaningful patent risk for competitors in the PBM technology space.
Ready to Strengthen Your Health Tech Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision in health technology.
References
- United States Court of Appeals for the Federal Circuit — Rule 36 Explained
- U.S. Patent and Trademark Office — Patent US10817920B2
- Cornell Legal Information Institute — Alice Corp. v. CLS Bank International (2014)
- PACER — Case No. 23-1024
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.